The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Identification of seven serum microRNAs from a genome‐wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas
Abstract
The involvement of circulating microRNAs (miRNAs) in cancer and their potential as biomarkers of diagnosis and prognosis are becoming increasingly appreciated; however, little is known about circulating miRNA profiles in astrocytomas. In our study, we performed genome‐wide serum miRNA analysis by the Solexa sequencing followed by validation conducted in the training and verification sets with a stem‐loop quantitative reverse‐transcription PCR (RT‐qPCR) assay from serum samples of 122 untreated astrocytomas patients (WHO grades III–IV) and 123 normal controls. Identified miRNAs were subsequently examined in 55 grade II, 15 grade I astrocytomas, 11 astrogliosis, 42 other primary brain tumors and 8 tumor tissues from grades II–IV astrocytomas. In addition, paired serum samples before and after operation were collected from 14 malignant astrocytomas to determine the effect of surgery on the miRNAs' levels. A marked difference in serum miRNA profile was observed between high‐grade astrocytomas and normal controls. Seven miRNAs were validated by RT‐qPCR assay to be significantly decreased in grades II–IV patients (p < 0.001), including miR‐15b*, miR‐23a, miR‐133a, miR‐150*, miR‐197, miR‐497 and miR‐548b‐5p, and the seven‐miRNA panel demonstrated a high sensitivity (88.00%) and specificity (97.87%) for malignant astrocytomas prediction. These identified miRNAs also exhibited a global decrease in tumor tissues relative to normal tissues. Furthermore, these miRNAs in serum were markedly elevated after operation (p < 0.001). In addition, some of these serum miRNAs were significantly different between malignant and benign cases, astrogliosis and other primary brain tumors. The seven serum miRNAs identified in our study hold potential as noninvasive biomarker for malignant astrocytomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hu, Z., Chen, X., Zhao, Y., Tian, T., Jin, G., Shu, Y., Chen, Y., Xu, L., Zen, K., Zhang, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9342 · Cited by 798
Self-citationMalzkorn, B., Wolter, M., Liesenberg, F., Grzendowski, M., Stühler, K., Meyer, H. E., & Reifenberger, G. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00328.x · Cited by 352
Cited by
Clinical relevance of circulating cell-free microRNAs in cancer
Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.5 · Cited by 969
MicroRNAome genome: A treasure for cancer diagnosis and therapy
Berindan‐Neagoe, I., Monroig, P. D. C., Pasculli, B., & Calin, G. A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21244 · Cited by 522
Carbon nanotubes: a novel material for multifaceted applications in human healthcare
Kumar, S., Rani, R., Dilbaghi, N., Tankeshwar, K., & Kim, K.-H. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00517a · Cited by 397
A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool
Manterola, L., Guruceaga, E., Pérez-Larraya, J. G., González-Huarriz, M., Jauregui, P., Tejada, S., Diez-Valle, R., Segura, V., Samprón, N., Barrena, C., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not218 · Cited by 345
Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy
Cheng, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.001 · Cited by 334
Metadata
- Authors
- Yang, C., Wang, C., Chen, X., Chen, S., Zhang, Y., Zhi, F., Wang, J., Li, L., Zhou, X., Li, N., Pan, H., Zhang, J., Zen, K., Zhang, C., & Zhang, C.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2012-06-26
- Volume
- 132
- Issue
- 1
- Pages
- 116-127
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1977232125
- Cited by
- 191
- References
- 2
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.